|
| Human Complement Component C2 Protein (LTP10360) |
|
| LTP10360 |
|
| 100ug |
|
|
$519 In stock |
| Single nucleotide polymorphism (SNP) of complement component 2 (C2) has been found to be significantly associated with hepatocellular carcinoma (HCC). Significantly lower C2 expression was found at HCC compared to healthy controls, and C2 was associated with TNM stages. Higher C2 expression was significantly associated with better prognosis, and multivariate analysis showed that C2 was also an independent factor for the prognosis of HCC. |
| Recombinant Human Complement Component C2 Protein is expressed from Expi293 with His tag at the C-terminal. It contains Ala21-Leu752. |
|
| Complement Component C2 |
|
| Human |
|
| P06681-1 |
|
| Ala21-Leu752 |
|
| The protein has a predicted MW of 82.2 kDa (Pro form). Due to glycosylation, the protein migrates to 83-90 kDa (Pro form) based on the Tris-Bis PAGE result. |
|
| 0 |
|
| C-His |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
